---
title: "AHA 2024: Spironolactone misses primary endpoints in CLEAR SYNERGY trial"
date: "2024-11-18T16:15:46.000Z"
publishedDate: "18 novembre 2024"
summary: "Routine use of the blood pressure medication spironolactone among patients who have undergone percutaneous coronary intervention following acute myocardial infarction (MI) may reduce heart failure, but is not likely to reduce mortality, recurrent MI or stroke. These are among the latest findings of the CLEAR SYNERGY (OASIS 9) trial, presented by Sanjit S Jolly (McMaster [&#8230;] The post AHA 2024: Spironolactone misses primary endpoints in CLEAR SYNERGY trial appeared first on Cardiovascular News ."
importance: ""
sourceUrl: "https://cardiovascularnews.com/aha-2024-spironolactone-synergy-trial/"
tags: ["France", "Actualité", "Cardiovascular News — Latest"]
permalink: "/papers/2024-11-18-aha-2024-spironolactone-misses-primary-endpoints-in-clear-synergy-trial"
imageUrl: "https://cardiovascularnews.com/wp-content/uploads/sites/14/2024/11/SanjitJollyM.D.M_edited1.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/aha-2024-spironolactone-synergy-trial/"
---

![AHA 2024: Spironolactone misses primary endpoints in CLEAR SYNERGY trial](https://cardiovascularnews.com/wp-content/uploads/sites/14/2024/11/SanjitJollyM.D.M_edited1.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/aha-2024-spironolactone-synergy-trial/*

## L’essentiel

Routine use of the blood pressure medication spironolactone among patients who have undergone percutaneous coronary intervention following acute myocardial infarction (MI) may reduce heart failure, but is not likely to reduce mortality, recurrent MI or stroke. These are among the latest findings of the CLEAR SYNERGY (OASIS 9) trial, presented by Sanjit S Jolly (McMaster [&#8230;] The post AHA 2024: Spironolactone misses primary endpoints in CLEAR SYNERGY trial appeared first on Cardiovascular News .

## Lien source

https://cardiovascularnews.com/aha-2024-spironolactone-synergy-trial/
